The FDA has issued a complete response letter (CRL) to a new drug application (NDA) for Dasynoc for the treatment of chronic ...

A CML diagnosis, often striking young Indian adults, is now more manageable. This guide emphasizes empowering patients by asking five crucial questions to their oncologist. These queries cover ...

December 7, 2009 (New Orleans, Louisiana) — Tyrosine kinase inhibitors that target BCR-ABL mutations, such as imatinib (Gleevec), have become standard therapy in the treatment of chronic myeloid ...

Real world evidence on treatment efficacy and safety of tyrosine kinase inhibitors in patients with chronic myeloid leukemia.

Comparative clinical and molecular outcomes of first, second, and third-generation tyrosine kinase inhibitors in chronic myeloid leukemia: A comprehensive Bayesian network meta-analysis. Hazard ratios ...

Chronic Myeloid Leukemia is a type of blood cancer that once used to be considered fatal disease, but with a clinical trial ...